Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.12. | KTTA stock touches 52-week low at $2.72 amid market challenges | 5 | Investing.com | ||
27.11. | KTTA stock touches 52-week low at $2.87 amid market challenges | 1 | Investing.com | ||
27.11. | KTTA-Aktie erreicht 52-Wochen-Tief bei 2,87 US-Dollar | - | Investing.com Deutsch | ||
PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
26.11. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
20.11. | Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 1 | GlobeNewswire (USA) | ||
15.11. | KTTA-Aktie erreicht 52-Wochen-Tief bei 3,19 US-Dollar | 4 | Investing.com Deutsch | ||
15.11. | KTTA stock touches 52-week low at $3.19 amid market challenges | 1 | Investing.com | ||
13.11. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
08.11. | KTTA stock touches 52-week low at $3.4 amid market challenges | 1 | Investing.com | ||
25.10. | KTTA stock touches 52-week low at $3.6 amid market challenges | 2 | Investing.com | ||
07.10. | Pasithea Therapeutics files to sell 3.74M shares of common stock for holders | 2 | Seeking Alpha | ||
27.09. | Pasithea Therapeutics drops 19% on $5M private placement | 2 | Seeking Alpha | ||
27.09. | Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 6 | GlobeNewswire (USA) | ||
26.09. | Pasithea Announces Positive Initial Data From Phase 1 Trial Of PAS-004 In Advanced Cancer; Stock Up | 2 | RTTNews | ||
26.09. | Why Is Pasithea Therapeutics Stock Surging On Thursday? | 2 | Benzinga.com | ||
26.09. | Pasithea Therapeutics Corp. - 8-K, Current Report | 3 | SEC Filings | ||
26.09. | Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 129 | GlobeNewswire (Europe) | -- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related... ► Artikel lesen | |
09.09. | Pasithea reports positive results in PAS-004 toxicity studies | 2 | Investing.com | ||
09.09. | Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies | 1 | GlobeNewswire (USA) | ||
04.09. | KTTA stock touches 52-week low at $4.36 amid market challenges | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
OCUGEN | 0,718 | -2,45 % | Ocugen: Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
GENPREX | 1,820 | 0,00 % | Genprex, Inc.: Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer | Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial
Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen |